Abstract
Background
Methods
Results
Conclusions
Supplementary Information
Notes
Ethics Statement
This study was approved by the Institutional Review Board of Seoul National University Bundang Hospital (IRB No. B-2012-652-309), and the requirement for informed consent was waived.
Availability of Data and Material
The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.
Author Contributions
Conceptualization: KK (Kennichi Kakudo), SYP. Data curation: HYN. Formal analysis: HYN. Investigation: HYN, MH, SS, KK (Kaori Kameyama), CKJ, SJS, SA, JFH, YZ, ZL. Methodology: AB, HYN. Project administration: HYN, AB. Resources: MH, SS, KK (Kaori Kameyama), CKJ, SJS, SA, JFH, YZ, ZL. Supervision: AB, KK (Kennichi Kakudo), SYP. Visualization: HYN. Writing—original draft: HYN. Writing—review & editing: AB, KK (Kennichi Kakudo), SYP. Approval of final manuscript: all authors.
References
Table 1.
FNAC diagnostic category | FA (n = 112) |
FTC |
p-valuea | p-valueb | |||
---|---|---|---|---|---|---|---|
FTC all (n = 110) | MIFTC (n = 67) | AIFTC (n = 20) | WIFTC (n = 23) | ||||
Original diagnoses | |||||||
I | 3 (2.7) | 4 (3.6) | 3 (4.5) | 1 (5.0) | 0 | .720 | > .999 |
II | 31 (27.7) | 12 (10.9) | 8 (11.9) | 3 (15.0) | 1 (4.3) | .002c | .762 |
III | 31 (27.7) | 30 (27.3) | 21 (31.3) | 5 (25.0) | 4 (17.4) | .946 | .231 |
IV | 42 (37.5) | 57 (51.8) | 30 (44.8) | 10 (50.0) | 17 (73.9) | .032c | .065 |
V | 5 (4.5) | 3 (2.7) | 2 (3.0) | 1 (5.0) | 0 | .722 | > .999 |
VI | 0 | 4 (3.6) | 3 (4.5) | 0 | 1 (4.3) | .059 | .647 |
Revised diagnoses | |||||||
I | 5 (4.5) | 5 (4.5) | 4 (6.0) | 1 (5.0) | 0 | .977 | .647 |
II | 30 (26.8) | 12 (10.9) | 8 (11.9) | 0 | 4 (17.4) | .003c | .762 |
III | 27 (24.1) | 25 (22.7) | 18 (26.9) | 4 (20.0) | 3 (13.0) | .685 | .196 |
IV | 50 (44.6) | 62 (56.4) | 32 (47.8) | 14 (70.0) | 16 (69.6) | .107 | .023c |
V | 0 | 4 (3.6) | 3 (4.5) | 1 (5.0) | 0 | .059 | > .999 |
VI | 0 | 2 (1.8) | 2 (3.0) | 0 | 0 | .244 | .519 |
Values are presented as number (%).
FNAC, fine needle aspiration cytology; FA, follicular adenoma; FTC, follicular thyroid carcinoma; MIFTC, minimally invasive follicular thyroid carcinoma; AIFTC, encapsulated angioinvasive follicular thyroid carcinoma; WIFTC, widely invasive follicular thyroid carcinoma.
Table 2.
Clinical and cytologic parameters | FA (n = 107) |
FTC |
p-valuea | p-valueb | |||
---|---|---|---|---|---|---|---|
FTC all (n = 105) | MIFTC (n = 63) | AIFTC (n = 19) | WIFTC (n = 23) | ||||
USG | .001c | .644 | |||||
Low suspicious | 37 (34.6) | 17 (16.2) | 11 (17.5) | 3 (15.8) | 3 (13.0) | ||
Intermediate to high suspicious | 49 (45.8) | 70 (66.7) | 41 (65.1) | 11 (57.9) | 18 (78.3) | ||
NA | 21 (19.6) | 18 (17.1) | 11 (17.5) | 5 (26.3) | 2 (8.7) | ||
Tumor size (cm) | 3.2 (0.6–9.0) | 3.5 (0.7–8.5) | 3.3 (0.7–8.5) | 3.8 (0.8–6.5) | 4.0 (1.4–8.2) | .128 | .022c |
Cellularity ≥ 60 cells | 97 (90.7) | 95 (90.5) | 56 (88.9) | 19 (100) | 20 (87.0) | .965 | .736 |
Pattern/arrangement | |||||||
Microfollicles ≥ 50% | 49 (45.8) | 65 (61.9) | 37 (58.7) | 13 (68.4) | 15 (65.2) | .019c | .412 |
Microfollicles in trabecular arrangement | 37 (34.6) | 46 (43.8) | 27 (42.9) | 8 (42.1) | 11 (47.8) | .169 | .810 |
Solid or trabecular pattern | 57 (53.3) | 54 (51.4) | 32 (50.8) | 10 (52.6) | 12 (52.2) | .788 | .873 |
Dyshesive cells, extensive | 9 (8.4) | 22 (21.0) | 11 (17.5) | 6 (31.6) | 5 (21.7) | .010c | .282 |
Macrofollicles ≥ 50% | 13 (12.1) | 8 (7.6) | 5 (7.9) | 0 | 3 (13.0) | .270 | >.999 |
Nuclear features | |||||||
Nuclear crowding, marked | 14 (13.1) | 29 (27.6) | 17 (27.0) | 6 (31.6) | 6 (26.1) | .009c | .859 |
Nuclear enlargement | 74 (69.2) | 80 (76.2) | 43 (68.3) | 17 (89.5) | 20 (87) | .251 | .017c |
Nuclear pleomorphism | 12 (11.2) | 23 (21.9) | 15 (23.8) | 5 (26.3) | 3 (13) | .036c | .563 |
Nuclear hyperchromatism | 35 (32.7) | 44 (41.9) | 19 (30.2) | 12 (63.2) | 13 (56.5) | .166 | .003c |
Coarse chromatin | 23 (21.5) | 29 (27.6) | 17 (27.0) | 9 (47.4) | 3 (13.0) | .300 | .859 |
Prominent nucleoli | 2 (1.9) | 8 (7.6) | 5 (7.9) | 3 (15.8) | 0 | .059 | > .999 |
Colloid quantity | .572 | .503 | |||||
Absent | 61 (57.0) | 68 (64.8) | 41 (65.1) | 9 (47.4) | 18 (78.3) | ||
Thin | 34 (31.8) | 28 (26.7) | 16 (25.4) | 9 (47.4) | 3 (13.0) | ||
Thick | 9 (8.4) | 8 (7.6) | 6 (9.5) | 1 (5.3) | 1 (4.3) | ||
Thin and thick | 3 (2.8) | 1 (1.0) | 0 | 0 | 1 (4.3) | ||
Colloid quantity | .556 | > .999 | |||||
Absent to focal | 93 (86.9) | 94 (89.5) | 56 (88.9) | 16 (84.2) | 22 (95.7) | ||
Extensive | 14 (13.1) | 11 (10.5) | 7 (11.1) | 3 (15.8) | 1 (4.3) | ||
Cystic change | 6 (5.6) | 8 (7.6) | 7 (11.1) | 1 (5.3) | 0 | .555 | .140 |
Values are presented as number (%) or mean (range).
FA, follicular adenoma; FTC, follicular thyroid carcinoma; MIFTC, minimally invasive follicular thyroid carcinoma; AIFTC, encapsulated angioinvasive follicular thyroid carcinoma; WIFTC, widely invasive follicular thyroid carcinoma; USG, ultrasonography; NA, not available.